Edition:
United Kingdom

Innate Pharma SA (IPH.PA)

IPH.PA on Paris Stock Exchange

7.85EUR
19 Nov 2018
Change (% chg)

€0.00 (+0.06%)
Prev Close
€7.84
Open
€7.90
Day's High
€8.19
Day's Low
€7.64
Volume
420,245
Avg. Vol
297,261
52-wk High
€9.44
52-wk Low
€4.33

Select another date:

Tue, Oct 23 2018

Photo

AstraZeneca digs deeper into cancer with Innate stake

LONDON/PARIS AstraZeneca is ploughing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma , which includes the British group buying a 9.8 percent stake in the French biotech company.

AstraZeneca digs deeper into cancer with Innate stake

LONDON/PARIS AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company.

UPDATE 2-AstraZeneca digs deeper into cancer with Innate stake

* Innate shares jump 29 percent (Updates with executive interviews, latest shares)

AstraZeneca to buy 9.8 pct stake in France's Innate Pharma

PARIS, Oct 23 British drugmaker AstraZeneca will buy a newly-issued equity stake of 9.8 percent in smaller French peer Innate Pharma, strengthening its presence in the field of immuno-oncology.

BRIEF-Innate Pharma: Phase II Results From Monalizumab/Cetuximab In Head And Neck Cancer

* INNATE PHARMA ANNOUNCED ON SATURDAY PHASE II RESULTS FROM MONALIZUMAB/CETUXIMAB IN HEAD AND NECK CANCER

BRIEF-Innate Pharma Publishes Phase 1 IPH4102 Results

* REPORTED ON SATURDAY IPH4102 PHASE 1 RESULTS IN ADVANCED CUTEANOUS T CELL LYMPHOMA

Select another date: